Relay Therapeutics (RLAY) director granted options on 32,947 shares at $14.09

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Relay Therapeutics, Inc. director Alexis Borisy reported receiving a stock option award covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 8, 2036.

According to the filing, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that grant date. This is a compensation-related grant, not an open-market purchase or sale of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Borisy Alexis

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,947	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,947 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 32,947 shares Exercise price: $14.09 per share Expiration date: June 8, 2036 +3 more

6 metrics

Option grant size 32,947 shares Stock Option (Right to Buy) granted June 9, 2026

Exercise price $14.09 per share Conversion or exercise price of stock option

Expiration date June 8, 2036 Option expiration date

Underlying shares 32,947 shares Underlying common stock for the option

Shares after transaction 32,947 derivative securities Total options held following this grant

Transaction code A Grant, award, or other acquisition of derivatives

Key Terms

Stock Option (Right to Buy), grant date, vests in full, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant date financial

"granted on June 9, 2026 with respect to 32,947 shares"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vests in full financial

"and vests in full on the earlier to occur of (a) the first anniversary"

annual meeting of stockholders financial

"or (b) the date of the next annual meeting of stockholders following the grant date"

derivative securities financial

"transaction_type: derivative"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borisy Alexis

(Last)

(First)

(Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.09	06/09/2026		A		32,947		⁽¹⁾	06/08/2036	Common Stock	32,947	$0	32,947	D

Explanation of Responses:

1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Relay Therapeutics (RLAY) disclose in this Form 4?

Relay Therapeutics disclosed that director Alexis Borisy received a stock option grant for 32,947 shares of common stock. The award is a compensation-related grant, not an open-market trade, and was reported as an acquisition of derivative securities.

What is the exercise price of Alexis Borisy’s new options in Relay Therapeutics (RLAY)?

The stock option grant to Alexis Borisy has an exercise price of $14.09 per share. This means he can buy Relay Therapeutics common stock at $14.09 once the options vest and are exercised, subject to the award’s terms.

How many Relay Therapeutics (RLAY) shares are covered by Alexis Borisy’s option grant?

The option grant covers 32,947 shares of Relay Therapeutics common stock. These are underlying shares that may be acquired in the future if the options vest and are exercised under the terms of the award agreement.

When do Alexis Borisy’s Relay Therapeutics (RLAY) options vest?

The options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders. This single vesting date applies to the entire 32,947-share option award.

When do the newly granted Relay Therapeutics (RLAY) options expire?

The stock option granted to Alexis Borisy expires on June 8, 2036. After this expiration date, any unexercised portion of the 32,947-share option award can no longer be exercised to purchase Relay Therapeutics common stock.

Is Alexis Borisy’s Relay Therapeutics (RLAY) Form 4 transaction a market buy or sell?

The Form 4 reports a grant of stock options as compensation, not a market buy or sale. The transaction code is “A,” indicating a grant or award acquisition of derivative securities rather than an open-market purchase or disposition of common shares.